Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis
- 2 September 2013
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 20 (5) , 566-576
Abstract
The objective of this paper is to investigate four-year outcomes of interferon beta (IFNB)-treated patients with multiple sclerosis (MS) according to their clinical or magnetic resonance imaging (MRI) activity status at first year of treatment. A total of 370 patients with MS duration ≤5 years before IFNB start were followed-up for four years. The optimal threshold for one-year MRI activity that more accurately predicted subsequent relapses or disability worsening was identified. The risk of relapses and disability worsening after the first year was then estimated by propensity score (PS)-adjusted analyses in patients fulfilling European Medicines Agency (EMA) criteria for second-line escalation and in those with isolated MRI activity. A total of 192 (51.9%) patients relapsed, and 66 (17.8%) worsened in disability from year 1 to 4 of follow-up. The more accurate threshold for one-year MRI activity was the occurrence of ≥1 enhancing or ≥2 new T2-lesions. An increased risk of relapses and disability worsening was found in either patients fulfilling EMA criteria (hazard ratio (HR) = 3.69, and HR = 6.02) and in those experiencing isolated MRI activity (HR = 3.15, and HR = 5.31) at first year of treatment, when compared with stable patients (all p values <0.001). The four-year outcomes of patients with isolated MRI activity did not differ from those fulfilling EMA criteria at first year of IFNB treatment.Keywords
This publication has 34 references indexed in Scilit:
- Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trialThe Lancet Neurology, 2012
- Multiple sclerosis therapeutic strategiesNeurology Clinical Practice, 2011
- Measures in the first year of therapy predict the response to interferon β in MSMultiple Sclerosis Journal, 2009
- Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosisThe Lancet Neurology, 2009
- Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyThe Lancet, 2007
- Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patientsAnnals of Neurology, 2006
- Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple SclerosisNew England Journal of Medicine, 2000
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993